Office Of New Drug Chemistry Reorganization Creates "PALS" For Industry
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's restructuring of the Office of New Drug Chemistry includes adding dedicated chemistry, manufacturing and controls reviewers within the premarketing and postmarketing divisions